Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

Gilead Sciences has developed an industry-leading HIV portfolio in recent years with its megablockbuster daily treatment ...

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...

– New Data Showcase Safety Profile of Twice-Yearly Lenacapavir for Pre-Exposure Prophylaxis (PrEP) with Other Medications and Recruitment Strategies for PURPOSE 5 – – Five-Year BICSTaR Results Offer ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

B/F/TAF shows lower ART switching rates and higher persistence among HIV patients, especially those with mental health or substance use disorders. Medicare claims data analysis indicates B/F/TAF has ...

HOUSTON — With President Trump's "Big, Beautiful Bil l," making major cuts to Medicaid, health care professionals and patients are warning of the potentially deadly consequences for people living with ...